Israeli Researchers Closing in On Cure for Leukemia With New ‘Breakthrough’
A breakthrough cancer study in which patients suffering from a form of leukemia saw their diseases go into remission after they were treated with genetically modified T-cells has deep roots in Israel.
One of the first in the world to work on the innovative adaptive immunotherapy technique to treat cancer, which was recently hailed worldwide as a potentially “extraordinary” development, was Weizmann Institute’s Prof. Zelig Eshhar.
Speaking on Israel Radio, Eshhar said he was very heartened to hear about the results of the study at the University of Pennsylvania.
In an article in the journal Science Translational Medicine, a team at the University of Pennsylvania’s Abramson Cancer Center and the Perelman School of Medicine reported that 27 out of 29 patients with an advanced blood cancer saw their cancers go into remission or disappear altogether when they received genetically modified T-cells that were equipped with synthetic molecules called chimeric antigen receptors, or CARs. Those T-cells were able to target and destroy the tumor cells – specifically the ones that were responsible for the acute lymphoblastic leukemia the patients were suffering from.
FOR ENTIRE ARTICLE CLICK LINKClick here for the Top 12 Moments in Jewish History...LET THE ADVENTURE BEGIN! »